Apigenin: a natural molecule at the intersection of sleep and aging.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and preliminary human studies without systematic methodology
PubMed 38476603 · doi:10.3389/fnut.2024.1359176
What was done
This narrative review summarizes preclinical and human literature evaluating the natural flavonoid apigenin. The authors synthesized mechanistic and phenotypic data across animal models (mice, rats, flies, worms) and examined human data from observational dietary intake cohorts and clinical trials of chamomile extract, focusing on NAD+ metabolism, CD38 inhibition, sleep, and longevity.
What was found
The abstract reports no numerical data, confidence intervals, or specific effect sizes. It qualitatively notes that apigenin inhibits the NAD+-degrading enzyme CD38, boosts NAD+ in mice, improves memory in aged mice, reduces tumor growth in breast cancer xenografts, and extends lifespan in flies and worms. For humans, it notes that chamomile extract has been reported to reduce anxiety, pain, and mood disturbances, and dietary apigenin correlates positively with adult sleep quality.
Why it matters
Highlights apigenin as a candidate compound that bridges metabolic aging pathways (specifically CD38-mediated NAD+ decline) with neurobehavioral outcomes like sleep regulation.
Limits
The review relies primarily on non-human model organisms whose longevity and metabolic dynamics do not directly translate to humans. Human data cited are largely indirect (using chamomile extract rather than pure apigenin) or cross-sectional/correlational, lacking randomized controlled trial evidence for pure apigenin supplementation on hard aging or sleep endpoints.
Cited by
- context Apigenin and chamomile act to quiet or downregulate frontal cortex activity to facilitate sleep onset.